skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 52  for All Library Resources

Results 1 2 3 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Trial of Tocilizumab in Giant-Cell Arteritis
Material Type:
Article
Add to My Research

Trial of Tocilizumab in Giant-Cell Arteritis

The New England journal of medicine, 2017-07, Vol.377 (4), p.317-328 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1613849 ;PMID: 28745999

Full text available

2
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Material Type:
Article
Add to My Research

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

New England Journal of Medicine, 2020-12, Vol.383 (24), p.2333-2344 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2028836 ;PMID: 33085857

Digital Resources/Online E-Resources

3
Treatment failure in giant cell arteritis
Material Type:
Article
Add to My Research

Treatment failure in giant cell arteritis

Annals of the rheumatic diseases, 2021-11, Vol.80 (11), p.1467-1474 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-220347 ;PMID: 34049857

Full text available

4
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Material Type:
Article
Add to My Research

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2022-05, Vol.81 (5), p.653-661 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. 2022 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-221865 ;PMID: 35264321

Full text available

5
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
Material Type:
Article
Add to My Research

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

Rheumatology (Oxford, England), 2022-07, Vol.61 (7), p.2915-2922 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2021 ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/keab780 ;PMID: 34718434

Full text available

6
Case 18-2023: A 19-Year-Old Woman with Dyspnea and Tachypnea
Material Type:
Article
Add to My Research

Case 18-2023: A 19-Year-Old Woman with Dyspnea and Tachypnea

The New England journal of medicine, 2023-06, Vol.388 (24), p.2275-2286 [Peer Reviewed Journal]

Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMcpc2300894 ;PMID: 37314709

Full text available

7
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
Material Type:
Article
Add to My Research

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

Arthritis research & therapy, 2021-01, Vol.23 (1), p.8-8, Article 8 [Peer Reviewed Journal]

COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-020-02377-8 ;PMID: 33407817

Full text available

8
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
Material Type:
Article
Add to My Research

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Arthritis research & therapy, 2023-10, Vol.25 (1), p.1-199, Article 199 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-023-03177-6 ;PMID: 37840134

Full text available

9
Case 3-2021: A 48-Year-Old Man with Transient Vision Loss
Material Type:
Article
Add to My Research

Case 3-2021: A 48-Year-Old Man with Transient Vision Loss

The New England journal of medicine, 2021-01, Vol.384 (4), p.363-372 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMcpc2002416 ;PMID: 33503346

Full text available

10
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
Material Type:
Article
Add to My Research

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

Rheumatology and therapy., 2020-12, Vol.7 (4), p.793-810 [Peer Reviewed Journal]

The Author(s) 2020 ;The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2198-6576 ;EISSN: 2198-6584 ;DOI: 10.1007/s40744-020-00227-2 ;PMID: 32844378

Full text available

11
Pearls & Oy-sters: Neuro-Sweet disease presenting as ischemic stroke and aseptic meningitis
Material Type:
Article
Add to My Research

Pearls & Oy-sters: Neuro-Sweet disease presenting as ischemic stroke and aseptic meningitis

Neurology, 2018-12, Vol.91 (23), p.e2197-e2199 [Peer Reviewed Journal]

2018 American Academy of Neurology ;2018 American Academy of Neurology 2018 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000006628 ;PMID: 30510029

Full text available

12
Design of the Tocilizumab in Giant Cell Arteritis Trial
Material Type:
Article
Add to My Research

Design of the Tocilizumab in Giant Cell Arteritis Trial

International Journal of Rheumatology, 2013-01, Vol.2013, p.912562-10 [Peer Reviewed Journal]

Copyright © 2013 Sebastian H. Unizony et al. ;COPYRIGHT 2013 Hindawi Limited ;Copyright © 2013 Sebastian H. Unizony et al. 2013 ;ISSN: 1687-9260 ;EISSN: 1687-9279 ;DOI: 10.1155/2013/912562 ;PMID: 23653652

Full text available

13
Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: A case report and review of the literature
Material Type:
Article
Add to My Research

Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: A case report and review of the literature

Pathology international, 2010-11, Vol.60 (11), p.755-759 [Peer Reviewed Journal]

2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd ;2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd. ;ISSN: 1320-5463 ;EISSN: 1440-1827 ;DOI: 10.1111/j.1440-1827.2010.02586.x ;PMID: 20946526

Full text available

14
Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
Material Type:
Article
Add to My Research

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis

Rheumatic & musculoskeletal diseases open, 2023-04, Vol.9 (2), p.e002923 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2022-002923 ;PMID: 37024237

Full text available

15
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
Material Type:
Article
Add to My Research

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database

Rheumatology and therapy., 2019-12, Vol.6 (4), p.599-610 [Peer Reviewed Journal]

The Author(s) 2019 ;The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2198-6576 ;EISSN: 2198-6584 ;DOI: 10.1007/s40744-019-00180-9 ;PMID: 31656021

Full text available

16
The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Material Type:
Article
Add to My Research

The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

Rheumatology and therapy., 2022-04, Vol.9 (2), p.497-508 [Peer Reviewed Journal]

The Author(s) 2021 ;2021. The Author(s). ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2198-6576 ;EISSN: 2198-6584 ;DOI: 10.1007/s40744-021-00411-y ;PMID: 34954809

Full text available

17
Case 7-2015: A 25-Year-Old Man with Oral Ulcers, Rash, and Odynophagia
Material Type:
Article
Add to My Research

Case 7-2015: A 25-Year-Old Man with Oral Ulcers, Rash, and Odynophagia

The New England journal of medicine, 2015-02, Vol.372 (9), p.864-872 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMcpc1413303

Full text available

18
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature
Material Type:
Article
Add to My Research

Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature

Clinical Rheumatology, 2016-01, Vol.35 (1), p.251-258 [Peer Reviewed Journal]

Clinical Rheumatology 2014 ;International League of Associations for Rheumatology (ILAR) 2015 ;ISSN: 0770-3198 ;EISSN: 1434-9949 ;DOI: 10.1007/s10067-014-2558-6 ;PMID: 24696366

Full text available

19
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
Material Type:
Article
Add to My Research

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients

Rheumatic & musculoskeletal diseases open, 2017, Vol.3 (2), p.e000570-e000570 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2017-000570 ;PMID: 29299342

Full text available

20
An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy
Material Type:
Article
Add to My Research

An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy

Annals of the rheumatic diseases, 2017-05, Vol.76 (5), p.898-905 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2016-210070 ;PMID: 27927642 ;CODEN: ARDIAO

Full text available

Results 1 - 20 of 52  for All Library Resources

Results 1 2 3 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (48)

Refine My Results

New Records 

  1. New From Last Month  (7)
  2. More options open sub menu

Language 

  1. Japanese  (3)
  2. Spanish  (1)
  3. More options open sub menu

Searching Remote Databases, Please Wait